SMYD3 and cancer: On the other hand, SMYD3-KO models, such as cells and xenograft mice models, revealed that SMYD3 genetic ablation reduces cancer cell resistance to CHTs, which is restored by exogenous expression of the WT protein, while the catalytically inactive form fails to do so.